|Videos|December 22, 2017

Psychoneuroimmunology: Bridging the Gap Between Psychiatrists & ID Physicians?

Robert Bransfield, MD, DLFAPA, explains how psychoneuroimmunology can work to bridge the gap between psychiatrists and infectious disease physicians to improve patient care.

Robert Bransfield, MD, DLFAPA, private practice, Psychiatry, in Red Bank, New Jersey, explains how psychoneuroimmunology can work to bridge the gap between psychiatrists and infectious disease physicians to improve patient care.

Interview Transcript (modified slightly for readability):

“The thought that infection can cause mental problems is foreign to the training of both psychiatrist and infectious disease doctors.

I was trained as a Freudian psychoanalyst—which was a very different kind of training—and most infectious disease doctors have very little psychiatric training. Your average infectious disease doctor maybe spent a month in a state hospital thirty years ago when he/she was a medical student and that might be the [extent] of their training.

So, there is this close correlation it seems between infections provoking the immune system, those immune effects causing psychiatric illness, which, in turn, may cause suicide or other psychiatric illness. We, therefore, see a disease, it starts in an infectious disease doctor’s office and ends up in a psychiatrist’s office. So, what we need is [for] infectious disease doctors to learn more psychoneuroimmunology and psychiatry, and psychiatrists need to learn more psychoneuroimmunology and infectious disease. And psychoneuroimmunology is what bridges the gap—looking at how the immune system affects brain functioning.

[For] psychoneuroimmunology we’re looking at how different transmitters affect brain functioning. We think of neurotransmitters, but one set is the neurotransmitters, the other set is the immune system; they’re two parallel communications that impact brain functioning, and we need to understand both. And once we look at that, we’ll get answers that we’ve previously been unable to find.”


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.